Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Class (Oral Contraceptives, Antiandrogens), By Surgery, By Distribution Channel, By Region, And Segment Forecasts, 2024

Description

Polycystic Ovarian Syndrome Treatment Market Growth & Trends:

The global polycystic ovarian syndrome treatment market size is expected to reach USD 6.99 billion by 2030, registering a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery.

Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.

Polycystic Ovarian Syndrome Treatment Market Report Highlights:

Constantly rising prevalence of PCOS is primarily driving the growth of this market across the globe
Initiatives undertaken by government bodies and market players to create awareness about benefits of early diagnosis and commercially available treatment for PCOS among women is boosting the market
Treatment of PCOS mainly includes lifestyle modification through balanced diet, exercise, and drugs such as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity agents, and antidepressants
Surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are preferred when patients do not respond to drug therapy
Insulin-sensitizing agents segment is dominating the market since these drugs are widely used for treatment of insulin resistance to prevent diabetes, which is a risk associated with PCOS
Oral Contraceptive Pills (OCPs) segment is expected to grow at the fastest rate followed by antiandrogen agents that are used for treating symptomatic conditions such as hirsutism and acne
North America is dominating the market followed by Europe. High awareness and availability of advanced healthcare facilities are factors responsible for the dominant share held by this region
Asia Pacific is expected to be the fastest growing region over the forecast period.Increasing government initiatives for raising awareness about symptoms & diagnosis of PCOS and available treatment are increasing the number of women being diagnosed with this syndrome in the region
China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players owing to presence of a large pool of obese female population, which is at high risk of PCOS

Product Code: GVR-2-68038-203-7

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Polycystic Ovarian Syndrome Treatment Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Polycystic Ovarian Syndrome Treatment Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Polycystic Ovarian Syndrome Treatment Market: Drug Class Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Polycystic Ovarian Syndrome Treatment Market: Drug Class Movement Analysis, 2023 & 2030 (USD Billion)
4.3. Oral Contraceptives
- 4.3.1. Oral Contraceptives Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4. Antiandrogens
- 4.4.1. Antiandrogens Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.5. Insulin-sensitizing Agent
- 4.5.1. Insulin-sensitizing Agent Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.6. Antidepressant
- 4.6.1. Antidepressant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.7. Anti-obesity
- 4.7.1. Anti-obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Polycystic Ovarian Syndrome Treatment Market: Surgery Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Polycystic Ovarian Syndrome Treatment Market: Surgery Movement Analysis, 2023 & 2030 (USD Billion)
5.3. Ovarian Wedge Resection
- 5.3.1. Ovarian Wedge Resection Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.4. Laparoscopic Ovarian Drilling
- 5.4.1. Laparoscopic Ovarian Drilling Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Polycystic Ovarian Syndrome Treatment Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Billion)
6.3. Hospital Pharmacy
- 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.4. Drug Store & Retail Pharmacy
- 6.4.1. Drug Store & Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5. Online Providers
- 6.5.1. Online Providers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Polycystic Ovarian Syndrome Treatment Market: Regional Estimates & Trend Analysis

7.1. Polycystic Ovarian Syndrome Treatment Market Share, By Region, 2023 & 2030 (USD Billion)
7.2. North America
- 7.2.1. North America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.2. U.S.
- 7.2.3. U.S. Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.4. Canada
  - 7.2.4.1. Canada Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.5. Mexico
  - 7.2.5.1. Mexico Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3. Europe
- 7.3.1. Europe Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.2. UK
  - 7.3.2.1. UK Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.3. Germany
  - 7.3.3.1. Germany Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.4. France
  - 7.3.4.1. France Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.2. China
  - 7.4.2.1. China Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.3. Japan
  - 7.4.3.1. Japan Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.4. India
  - 7.4.4.1. India Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.5. South Korea
  - 7.4.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.6. Australia
  - 7.4.6.1. Australia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Latin America
- 7.5.1. Latin America Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.2. Saudi Arabia
  - 7.6.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.3. UAE
  - 7.6.3.1. UAE Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.4. South Africa
  - 7.6.4.1. South Africa Polycystic Ovarian Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. AstraZeneca
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Bayer AG
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Merck KGaA.
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Abbott
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Pfizer, Inc
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Sanofi
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Bristol Myers Squibb Company
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Teva Pharmaceutical Industries Ltd
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Novartis AG
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Ferring B.V.
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives

Polycystic Ovarian Syndrome Treatment Market Size, Share & Trends Analysis Report By Drug Class (Oral Contraceptives, Antiandrogens), By Surgery, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030